Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

40%(2 trials)

Phase Distribution

Ph phase_2

17%

Ph phase_1

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

4(80.0%)

Phase 2Efficacy & side effects

1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Other(1)

Detailed Status

Completed5

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 14 (80.0%)

Phase 21 (20.0%)

Trials by Status

completed583%

unknown117%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_1

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

NCT01799278

completedphase_1

Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies

NCT01677559

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT01601535Phase 1

Study of MLN8237 in Combination With Irinotecan and Temozolomide

Completed

NCT01540682Phase 1

MLN8237 in Head and Neck Cancer

Completed

NCT03005262

MLN8237 for a Subject With Adenocarcinoma of the Prostate

Unknown

NCT01799278Phase 2

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Completed

NCT01677559Phase 1

Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies

Completed

NCT02444884Phase 1

MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6